Literature DB >> 35771558

CAR T-cell therapy: which product for which patient?

Paolo Strati1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35771558      PMCID: PMC9247365          DOI: 10.1182/blood.2022016676

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  10 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

3.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.

Authors:  Erin A Dean; Rahul S Mhaskar; Hong Lu; Mina S Mousa; Gabriel S Krivenko; Aleksandr Lazaryan; Christina A Bachmeier; Julio C Chavez; Taiga Nishihori; Marco L Davila; Farhad Khimani; Hien D Liu; Javier Pinilla-Ibarz; Bijal D Shah; Michael D Jain; Yoganand Balagurunathan; Frederick L Locke
Journal:  Blood Adv       Date:  2020-07-28

5.  Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.

Authors:  Stephen J Schuster; Jie Zhang; Hongbo Yang; Abhijit Agarwal; Wenxi Tang; Marcela Martinez-Prieto; Vamsi Bollu; David Kuzan; Richard T Maziarz; Marie José Kersten
Journal:  Leuk Lymphoma       Date:  2022-01-02

6.  Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.

Authors:  Jordan Gauthier; Nicolas Gazeau; Alexandre V Hirayama; Joshua A Hill; Vicky Wu; Aisling Cearley; Paula Perkins; Angela Kirk; Mazyar Shadman; Victor A Chow; Ajay K Gopal; Alexandria Hodges Dwinal; Staci Williamson; Jessie Myers; Andy Chen; Sarah Nagle; Brandon Hayes-Lattin; Levanto Schachter; David G Maloney; Cameron J Turtle; Mohamed L Sorror; Richard T Maziarz
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

7.  Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.

Authors:  Matthew J Frigault; Jorg Dietrich; Maria Martinez-Lage; Mark Leick; Bryan D Choi; Zachariah DeFilipp; Yi-Bin Chen; Jeremy Abramson; Jennifer Crombie; Philippe Armand; Lakshmi Nayak; Chris Panzini; Lauren S Riley; Kathleen Gallagher; Marcela V Maus
Journal:  Blood       Date:  2019-07-18       Impact factor: 25.476

8.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Authors:  Loretta J Nastoupil; Michael D Jain; Lei Feng; Jay Y Spiegel; Armin Ghobadi; Yi Lin; Saurabh Dahiya; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Alison R Sehgal; Andre Goy; Brian T Hill; Khoan Vu; Charalambos Andreadis; Javier Munoz; Jason Westin; Julio C Chavez; Amanda Cashen; N Nora Bennani; Aaron P Rapoport; Julie M Vose; David B Miklos; Sattva S Neelapu; Frederick L Locke
Journal:  J Clin Oncol       Date:  2020-05-13       Impact factor: 50.717

9.  Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.

Authors:  Qing Deng; Guangchun Han; Nahum Puebla-Osorio; Man Chun John Ma; Paolo Strati; Beth Chasen; Enyu Dai; Minghao Dang; Neeraj Jain; Haopeng Yang; Yuanxin Wang; Shaojun Zhang; Ruiping Wang; Runzhe Chen; Jordan Showell; Sreejoyee Ghosh; Sridevi Patchva; Qi Zhang; Ryan Sun; Frederick Hagemeister; Luis Fayad; Felipe Samaniego; Hans C Lee; Loretta J Nastoupil; Nathan Fowler; R Eric Davis; Jason Westin; Sattva S Neelapu; Linghua Wang; Michael R Green
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 87.241

10.  Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.

Authors:  Guillaume Cartron; Christopher P Fox; Fei Fei Liu; Ana Kostic; Jens Hasskarl; Daniel Li; Ashley Bonner; Yixie Zhang; David G Maloney; John Kuruvilla
Journal:  Exp Hematol Oncol       Date:  2022-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.